David A Engers

Title: David A Engers: Innovator in Nanocrystalline Formulations

Introduction

David A Engers is a notable inventor based in Collegeville, PA (US). He holds a total of 6 patents that focus on advancements in the field of nanocrystalline formulations, particularly in relation to human immunodeficiency virus (HIV) protease inhibitors. His work has significant implications for the treatment of HIV, showcasing his commitment to improving healthcare through innovative solutions.

Latest Patents

Engers' latest patents include methods of treating mammals using nanocrystalline formulations of HIV protease inhibitors. These formulations consist of nanoparticulate HIV protease inhibitors that incorporate a cellulosic surface stabilizer. The nanoparticulate formulations demonstrate an increased rate of dissolution in vitro and an enhanced rate of absorption in vivo. Additionally, they exhibit a decreased fed/fasted ratio variability and reduced variability in absorption. Engers' inventions also detail methods for creating these novel formulations, specifically targeting HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors.

Career Highlights

Throughout his career, Engers has worked with reputable companies such as Elan Pharma International Limited and Nawosystems LLC. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and formulations.

Collaborations

Engers has collaborated with notable professionals in his field, including W Mark Eickhoff and Karl R Mueller. These partnerships have likely enriched his research and development efforts, leading to impactful innovations.

Conclusion

David A Engers is a distinguished inventor whose work in nanocrystalline formulations has the potential to transform HIV treatment. His contributions to the field are marked by a commitment to innovation and collaboration, making him a significant figure in pharmaceutical advancements.